慢性淋巴白血病用药GS-1101 开始III期临床研究

2012-05-06 中国医药123网中国医药123网

Gilead科技公司开始GS-1101的III期临床研究，用于治疗慢性淋巴白血病（CLL）。此次研究共招募160名CLL患者，设置了随机和双盲的对照，将把GS-1101结合各种化疗方法用于治疗CLL患者。此次安慰剂控制研究的初级终末点为无进展生存率。 Gilead公司肿瘤及炎症治疗高级副总裁Roy Baynes说：“就我们目前得到的积极临床结果来讲，我们相信GS-1101能够为治疗CLL

Gilead科技公司开始GS-1101的III期临床研究，用于治疗慢性淋巴白血病（CLL）。

此次研究共招募160名CLL患者，设置了随机和双盲的对照，将把GS-1101结合各种化疗方法用于治疗CLL患者。

此次安慰剂控制研究的初级终末点为无进展生存率。

Gilead公司肿瘤及炎症治疗高级副总裁Roy Baynes说：“就我们目前得到的积极临床结果来讲，我们相信GS-1101能够为治疗CLL提供很好的帮助，我们希望同研究者密切合作，推动这种有潜力的治疗药的研发。”

GS-1101是一种针对肌醇磷脂3激酶特异性抑制剂。（生物谷Bioon.com）

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言

评论区 (7)

#插入话题

插入图片

[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2012-09-30 医生2402

#I期临床#

20 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2013-02-25 tastas

#III期临床研究#

38 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2012-07-14 huiwelcome

#II期临床研究#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2013-02-26 juliusluan78

#III#

37 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2012-05-07 ms3117646317107274

#S-1#

25 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2012-05-07 guihongzh

#II期临床#

28 0
[GetPortalCommentsPageByObjectIdResponse(id=1652684, encodeId=1d8416526842e, content=<a href='/topic/show?id=5b011018e07' target=_blank style='color:#2F92EE;'>#I期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10187, encryptionId=5b011018e07, topicName=I期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=fc1f24335670, createdName=医生2402, createdTime=Sun Sep 30 11:07:00 CST 2012, time=2012-09-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2050137, encodeId=0ed2205013ee1, content=<a href='/topic/show?id=581595e015' target=_blank style='color:#2F92EE;'>#III期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=38, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9570, encryptionId=581595e015, topicName=III期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=/v1.0.0/img/user_icon.png, createdBy=47c5349, createdName=tastas, createdTime=Mon Feb 25 00:07:00 CST 2013, time=2013-02-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1649949, encodeId=524b164994925, content=<a href='/topic/show?id=21a496002b' target=_blank style='color:#2F92EE;'>#II期临床研究#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9600, encryptionId=21a496002b, topicName=II期临床研究)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=891023951385, createdName=huiwelcome, createdTime=Sat Jul 14 19:07:00 CST 2012, time=2012-07-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1915760, encodeId=88e11915e6011, content=<a href='/topic/show?id=c5a89550ff' target=_blank style='color:#2F92EE;'>#III#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9550, encryptionId=c5a89550ff, topicName=III)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e68e415, createdName=juliusluan78, createdTime=Tue Feb 26 14:07:00 CST 2013, time=2013-02-26, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1477825, encodeId=c56214e782530, content=<a href='/topic/show?id=944315e85c0' target=_blank style='color:#2F92EE;'>#S-1#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=25, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=15785, encryptionId=944315e85c0, topicName=S-1)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a6477383481, createdName=ms3117646317107274, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1524529, encodeId=a52f1524529cc, content=<a href='/topic/show?id=4ba395994d' target=_blank style='color:#2F92EE;'>#II期临床#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9599, encryptionId=4ba395994d, topicName=II期临床)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=139811614978, createdName=guihongzh, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1594317, encodeId=ff16159431eef, content=<a href='/topic/show?id=b317956200' target=_blank style='color:#2F92EE;'>#III期#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=20, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=9562, encryptionId=b317956200, topicName=III期)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=智智灵药, createdTime=Mon May 07 15:07:00 CST 2012, time=2012-05-07, status=1, ipAttribution=)]
2012-05-07 智智灵药

#III期#

20 0

内科

外科

专科科室

热点

按科室浏览

临床工具

科研工具

其他工具

科研数智化

真实世界研究解决方案

数字化学术传播解决方案

其它

药械

慢性淋巴白血病用药GS-1101 开始III期临床研究

相关资讯

科室

工具

服务